Telix Pharmaceuticals Limited
TLX | NASDAQ
$11.92
+$0.61 (+5.39%)
Sep 22, 2026, 10:37 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q4 2025 Dec 30, 2025 | Q2 2025 Jun 29, 2025 | Q4 2024 Dec 30, 2024 | Q2 2024 Jun 29, 2024 | Q4 2023 Dec 30, 2023 | Q2 2023 Jun 29, 2023 | Q4 2022 Dec 30, 2022 | Q2 2022 Jun 29, 2022 | Q4 2021 Dec 30, 2021 | Q2 2021 Jun 29, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 691.36M | 620.44M | 593.11M | 594.24M | 188.96M | 281.71M | 220.83M | 136.05M | 24.05M | 4.69M | 2.91M |
Cost of Revenue | 334.74M | 293.02M | 304.77M | 208.45M | 65.08M | 57.74M | 130.02M | 91.16M | 39.62M | 23.54M | 14.09M |
Gross Profit | 356.63M | 327.42M | 288.34M | 385.8M | 123.88M | 223.98M | 90.81M | 44.89M | -15.57M | -18.86M | -11.18M |
Operating Income | -19.91M | 9.82M | 15.79M | 68.38M | 13.75M | -15.6M | 31.44M | -9.7M | -63.49M | -49.92M | -31.6M |
Interest Income | 3.29M | 3.32M | 3.62M | 10.25M | 610K | 566K | 453K | 214K | 1K | 89K | 74K |
Pretax Income | 42.36M | -645.3K | -7.35M | 46.91M | 9.14M | 15.39M | -12.3M | -27.92M | -70.7M | -61.99M | -37.05M |
Net Income | 55.51M | -7.25M | -3.48M | 38.24M | 11.68M | 19.53M | -14.32M | -33.19M | -70.89M | -48M | -32.51M |
Selling & General & Admin | 197.19M | 183.04M | 146.92M | 111.82M | 95.3M | 69.8M | 28.93M | 64.02M | 23.08M | 10.59M | 6.75M |
Research & Development | 179.34M | 134.56M | 123.96M | 75.25M | 45.78M | 98.4M | 30.45M | 33.01M | 24.84M | 20.47M | 13.67M |
Other Expenses | n/a | n/a | 1.68M | 130.35M | -30.96M | 35.7M | n/a | -42.44M | n/a | n/a | n/a |
Operating Expenses | 376.53M | 317.6M | 272.56M | 317.42M | 110.13M | 203.9M | 59.37M | 54.6M | 47.92M | 31.06M | 20.42M |
Interest Expense | 7.03M | 11.68M | 3.92M | 16.52M | 4.94M | 548K | 442K | 268K | 138K | 104K | 85K |
Selling & Marketing Expenses | n/a | n/a | 74.41M | 48.16M | 37.31M | 25.94M | 5.6M | 27.61M | 10.36M | 3.5M | 2.39M |
Cost & Expenses | 711.27M | 610.62M | 577.32M | 525.87M | 175.21M | 261.64M | 189.4M | 145.75M | 87.54M | 54.6M | 34.51M |
Income Tax Expense | -13.15M | 6.61M | 3.87M | 8.67M | -2.54M | -4.14M | 2.02M | 5.27M | 188K | -14M | -4.53M |
Shares Outstanding (Basic) | 339.22M | 338.78M | 337.2M | 331.23M | 334.23M | 323.73M | 317.62M | 316.34M | 307.33M | 283.02M | 281.02M |
Shares Outstanding (Diluted) | 356.89M | 338.78M | 337.2M | 345.19M | 350.75M | 323.73M | 317.62M | 316.34M | 307.33M | 283.02M | 281.02M |
EPS (Basic) | 0.16 | -0.02 | -0.01 | 0.12 | 0.03 | 0.06 | -0.05 | -0.10 | -0.23 | -0.17 | -0.12 |
EPS (Diluted) | 0.16 | -0.02 | -0.01 | 0.11 | 0.03 | 0.06 | -0.05 | -0.10 | -0.23 | -0.17 | -0.12 |
EBITDA | 17.3M | 28.92M | 8.91M | 82.78M | 40.29M | 22.99M | -8.57M | -24.99M | -67.83M | -59.26M | -33.88M |
EBIT | -19.91M | 11.03M | -1.76M | 78.46M | 36.63M | 19.2M | -11.86M | -27.65M | -70.57M | -61.89M | -36.69M |
Depreciation & Amortization | 37.2M | 17.89M | 10.67M | 4.32M | 3.66M | 2.09M | 3.29M | 2.66M | 2.74M | 2.63M | 2.82M |
Add to Watchlist
Select watchlists to add or remove TLX